Skip to main content
Equibles
BCTX logo

BCTX · BriaCell Therapeutics Corp.

Track BCTX — free

Use BCTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BCTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.04 -0.07 (-1.70%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Jun 9, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, the Company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to continue to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company's ability to raise such financial capital casts substantial doubt on the Company's ability to continue as a going concern.”
View the 10-Q filed Jun 9, 2026
Market Cap
$35.50M
Shares
8.70M
Volume · Oct 2 104.92K Avg daily vol (3M) 293.84K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.04 Open$4.17 Day$4.01–4.33 52W close$2.74–13.79 Avg vol 30d467K Short int792K · 9.1% float · 8.6d Short vol57% Last earningsOct 28, 2022 DataJan 2020–Oct 2026 Filing10-Q · Jun 9

Up next

Latest filing: 10-Q
filed Jun 9, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$30.68M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
1.8
Trailing earnings · reciprocal yield 56.7%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$22.80M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,843.5%
Year over year · more shares
Price change (1Y)
-68.5%
Trailing year
Short interest
9.1%
Latest settlement · 8.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg +9%
above
RSI (14) 53
neutral
MACD trend Positive
52-week position 12%
near low
Momentum
relative strength
Weak
1-month return +14%
trailing
6-month return −8%
trailing
YTD return −43%
this year
Relative strength −20%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.11% of float · ▲ +9.4% MoM · 8.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
27 holders — mid 3-yr range
Squeeze score 81
high risk · 0–100
Fundamentals
Poor
EPS growth −42%
Y/Y
Free cash flow $-28.6M
Quant / Vol
risk profile
Very High
Volatility 114%
annualized · 1-yr
Max drawdown −80%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Neutral
Price vs 50-day avg
+9% Bullish
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
12% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.11% of float · ▲ +9.4% MoM · 8.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $4 · 12% Range high $14
vs 200-day avg -5% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BCTX
BriaCell Therapeutics Corp.
this stock
$35.50M -43.2% — — 9.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
27
% held
47.1%
Net QoQ
-1.3M sh
Top holder
CITADEL ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
792.2K
Days to cover
8.6d
Change
+68.4K sh
View
Short Volume
Short vol %
57%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1.3K
Value
$4.7K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
46.0%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-26.3M
EPS diluted
$-62.19
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 26, 2026
This year
9
View
Exempt Offerings
Offering
$27.2M
Filed
Jun 15, 2021
View
Earnings & Events
Webcasts
Last webcast
Oct 28, 2022
View

Performance

5D 20D 120D MTD YTD
BCTX -6.5% +14.5% -7.8% -5.6% -43.2%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -6.3% +14.9% -19.9% -6.5% -56.0%
Key facts CIK 1610820 CUSIP 107930307 Visit website Investor relations